Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Dapagliflozin 10mg + Metformin Hydrochloride I.P. 500mg Tablets
Therapeutic Category
Antidiabetic, Diabetic
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹267/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Dapoflit M Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antidiabetic agent. This formulation is used in the management of Type 2 Diabetes Mellitus by improving glycemic control. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion, while Metformin decreases hepatic glucose production and enhances insulin sensitivity. Together, they help in maintaining blood sugar levels and support cardiovascular and renal health in diabetic patients.
Common side effects may include urinary tract infections, genital infections, nausea, diarrhea, abdominal discomfort, and increased urination. Rarely, hypoglycemia may occur, especially when combined with other antidiabetic drugs.
Indicated for patients with Type 2 Diabetes Mellitus when diet, exercise, and Metformin monotherapy do not provide adequate glycemic control. Also suitable as part of combination therapy for better blood sugar management.
Not recommended for patients with Type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with renal impairment. Adequate hydration should be maintained to reduce the risk of dehydration.
Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.
Composition : Dapagliflozin 5mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Fenofibrate I.P. 160mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg + Clopidogrel I.P. 75mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 80mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 10mg + Clopidogrel I.P. 75mg Tablets
Composition : Sitagliptin Phosphate I.P. 100mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 1000mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 500mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This antidiabetic combination has strong demand in the diabetes care segment, making it a high-potential product for medical distributors, wholesalers, and pharma franchise partners looking to expand in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes patients requiring dual therapy for better glycemic control. It strengthens their antidiabetic and chronic care portfolio.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Dapagliflozin 10mg + Metformin Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong long-term prescription demand, repeat sales, and stable chronic diabetes market growth when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this antidiabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, bulk procurement, pricing details, and distribution support services.